Hot Flash Remedy report

Hot Flash Remedy report

Heres what youll discover in The Hot Flash Remedy report: The herb from central Asia that can stop hot flashes in one week! (page 17) How your brain gets tricked into firing up the furnace and how to recalibrate it. (page 6) 7 lifestyle factors that increase your odds of suffering from hot flashes. (page 19) 9 food items that bring hot flashes on fast and furious! (page 10) The bean that actually makes hot flashes non-existent for women in other countries. (page 12) The secret ingredient in your fruit bowl that extinguishes the flame. (page 17) Why 6 meals a day are better than 3 and eating more often wont make you gain weight! (page 10) How common wildflowers hold the key to shutting down hot flashes. (page 16)

Hot Flash Remedy report Summary


4.6 stars out of 11 votes

Format: Ebook
Price: $27.77

My Hot Flash Remedy report Review

Highly Recommended

I usually find books written on this category hard to understand and full of jargon. But the writer was capable of presenting advanced techniques in an extremely easy to understand language.

I personally recommend to buy this ebook. The quality is excellent and for this low price and 100% Money back guarantee, you have nothing to lose.

Download Now

Tamoxifen and Breast Cancer Prevention

An assessment of quality of life showed no difference in depression scores between groups. Hot flushes were noted in 81 of the women on tamoxifen compared to 69 of the placebo group and the tamoxifen-associated hot flushes appeared to be of greater severity than those in the placebo group. Moderately bothersome or severe vaginal discharge was reported by 29 of the women in tamoxifen group and 13 in the placebo group. No differences in occurrence of irregular menses, nausea, fluid retention, skin changes, or weight gain or loss were reported.207'208

Perimenopausal transition

Perimenopause is defined as the two to eight years preceding menopause and the one year after the last menstrual period. It is characterized by a normal ovulatory cycle interspersed with anovulatory cycles. Menses become irregular, and heavy breakthrough bleeding can occur. Some women complain of hot flashes and vaginal dryness.

Shortterm effects of estrogen deficiency

The most common symptom of menopause is the hot flash, which occurs in 75 percent of women. Flashes are self-limited, with 50 to 75 percent of women having cessation of hot flashes within five years. B. Hot flashes typically begin as the sudden sensation of heat centered on the face and upper chest, which rapidly becomes generalized. The sensation of heat lasts from two to four minutes, is often associated with profuse perspiration and occasionally palpitations, and is often followed by chills and shivering. Hot flashes usually occur several times per day.

Treatment of menopausal symptoms with estrogen

Data from the WHI and the HERS trials has determined that continuous estrogen-progestin therapy increases the risk of breast cancer, coronary heart disease, stroke, and venous thromboembolism over an average follow-up of 5.2 years. As a result, the primary indication for estrogen therapy is for control of menopausal symptoms, such as hot flashes. 6. Treatment of vasomotor instability in women not taking estrogen Venlafaxine (Effexor), at doses of 75 mg daily, reduces hot flashes by 61 percent. Mouth dryness, anorexia, nausea, and constipation are common.

Background and Introduction

The female sex hormone estrogen plays an essential role in reproduction and is important for the overall maintenance of physiologic homeostasis in a woman's body.1'2 During menopause, which occurs in women at an average age of 51, the amount of estrogen produced by the ovaries decreases and this estrogen deficiency causes menstrual periods to become less frequent and then stop.3-5 The loss of estrogen is responsible for many of the uncomfortable symptoms associated with menopause, including hot flashes, mood swings or depression, sleep disorders, vaginal dryness, and urinary dysfunction.6 Osteoporosis or bone loss is another consequence of reduced estrogen levels after menopause.7-11 In women, bone density increases until ages 30-35,12 but slowly declines after menopause.13 Postmenopausal women are also at increased risk for coronary heart disease (CHD)14,15 and Alzheimer's disease,16-18 as a result of estrogen deficiency. The realization that the symptoms reported by postmenopausal...

Physiological Effects

The plateau stage of drug effects lasts 3-4 hours. The principal desired effect, according to most users, is a profound feeling of relatedness to the rest of the world. Most users experience this feeling as a powerful connection to those around them, as well as to the universe (Leister, Grob, Bravo, & Walsh, 1992). Although the desire for sex can increase, the ability to achieve arousal and orgasm is greatly diminished in both men and women (Buffum & Moser, 1986). MDMA has thus been termed a sensual, not a sexual, drug. The prescription drug sildenafil (Viagra) may be taken in order to counteract this effect, and may be sold along with MDMA (Weir, 2000) the successor medications involving sexual enhancement can be expected to be used in this manner. The array of physical effects and behaviors produced by MDMA is remarkably similar across mammalian species (Green et al., 1995) and includes mild psychomotor restlessness, bruxism, trismus, anorexia, diaphoresis, hot flashes, tremor, and...

Experimental Disease Models

The interaction of the estrogen receptor with its natural ligand, 17 -estradiol (E2), mediates a number of fundamental physiological processes, including regulation of the female reproductive system and the maintenance of skeletal and cardiovascular health. Pharmacological modulation of the estrogen receptor with the estrogens found in hormone replacement therapy (HRT) provides important clinical benefits in women for the treatment of hot flashes and osteoporosis. However, the increased risk of breast, uterine, and cardiovascular side effects that is associated with estrogen therapies has led to the development of ligands with improved risk-to-benefit ratios. These SERMs, such as tamoxifen and raloxifene, have demonstrated the ability to mimic estrogen in some tissues (bone, liver, and the cardiovascular system) while suppressing the effects of estrogen in other tissues (breast, uterus Figure 1). This unique tissue-selective profile has proven beneficial for the prevention and...

Development of Gabapentin for Epilepsy

After the gabapentin product launch, gabapentin was used extensively by physicians for treating epilepsy. Because of a relatively benign adverse event profile and few drug-drug interactions, it was also prescribed for off-label indications, including neuropathic pain, anxiety, and other psychiatric indications, essential tremor, spasticity, postsurgical pain, and prevention of postmenopausal hot flashes. None of these additional indications were supported in the gabapentin product labeling or approved by regulatory agencies until the FDA approved a supplemental NDA for gabapentin to treat postherpetic neuralgia in July 2001 (see Section, below).

Sleep Disturbance In

Diarrhea is a common complaint of patients living with opportunistic infections and can lead to fragmented and non-restful sleep, as can urinary frequency, hot flashes, muscle cramping, pruritus, dyspnea, and other physical complaints. Obstructive sleep ap-nea due to adenotonsillar hypertrophy has been estimated to have a prevalence of 7 among individuals living with HIV, even in the absence of obesity (Epstein et al., 1995). It has also been associated with increased neck fat hypertrophy, which is due to the deposit of adipose tissue around the neck as part of HIV-associated lipodystrophy (Schulz et al., 2003). Decreased levels of testosterone can also lead to insomnia.


Several preparations containing only 20 g of ethinyl estradiol are now available (Lo-Estrin 1 20, Mircette, Alesse, Aviane). These are often used for perimenopausal women who want contraception with the lowest estrogen dose possible. These preparations provide enough estrogen to relieve vasomotor flashes. Perimenopausal women often experience hot flashes and premenstrual mood disturbances during the seven-day pill-free interval. Mircette, contains 10 g of ethinyl estradiol on five of the seven placebo days, which reduces flashes and mood symptoms.


Bazedoxifene (TSE-424 Figure 10) is a novel SERM developed by Wyeth Pharmaceuticals that is currently in phase III clinical trials for the prevention and treatment of postmenopausal osteoporosis. It is an indole-based estrogen receptor ligand that has been stringently selected to ensure an improved profile over its predecessor raloxifene. It was developed using preclinical selection parameters, which included favorable effects on the skeleton and lipid metabolism, demonstrable mammary and uterine safety, and neutral effects on hot flashes.192 Bazedoxifene treatment maintains bone mineral density, preserves normal bone histology, increases bone compressive strength, and reduces total cholesterol levels in animal models.192-194 It lacks uterotropic activity194 and it blocks raloxifene-induced increases in uterine weight192 and inhibits E2-induced proliferation in MCF-7 breast cancer cells.192 Based on the favorable preclinical evaluation, it is suggested that bazedoxifene has the...